Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1994 2
1995 2
1996 4
1997 1
1998 8
1999 3
2000 8
2001 7
2002 5
2003 8
2004 7
2005 7
2006 2
2007 3
2008 3
2009 8
2010 2
2011 1
2012 8
2013 4
2014 4
2015 2
2016 1
2017 6
2018 1
2019 3
2020 1
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 9839298

120 results

Results by year

Filters applied: . Clear all
Page 1
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Iino Y, et al. Clin Exp Nephrol. 2003 Sep;7(3):221-30. doi: 10.1007/s10157-003-0241-3. Clin Exp Nephrol. 2003. PMID: 14586719 Clinical Trial.
Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
Kang SM, Youn JC, Chae SC, Park CG, Yang JY, Kim MH, Hong TJ, Kim CH, Kim JJ, Shin DG, Jeong JW, Yoon JH, Park SH, Kwon J, Cho SY. Kang SM, et al. Clin Ther. 2011 Dec;33(12):1953-63. doi: 10.1016/j.clinthera.2011.11.007. Epub 2011 Dec 2. Clin Ther. 2011. PMID: 22136978 Clinical Trial.
120 results